ESR1 and breast cancer: TNBC, representing 15–20% of all breast cancers [6], is the most aggressive subtype of BC, characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [7,8,9,10].